Although our study lacks follow-up data on γH2AX and 53BP1 foci in same CML patients, the potential increases in the long-term course in these patients may be similar to the numbers of γH2AX and 53BP1 foci in different CML patients at various stages. This evidence concerns the gene TP53BP1 and chronic myelogenous leukemia, BCR-ABL1 positive.